China’s Biopharma Homecoming
By James Strachan, Henry Thomas
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
False
Advertisement
Outsourcing
The Mindset for Success in Biopharma's New Multipolar World
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
The Confidentiality Barrier to AI-Enabled Drug Development
By Timothy Pas, Laure Descamps
July 27, 2026
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
3 min read
The Rise of China: From Science Cities to Global Ambition
By James Strachan, Kathryn Wighton
July 15, 2026
Daphne Smyth of Veristat on the rise of Chinese biopharma, regulatory realities, and what comes next
8 min read
Biopharma Vital Signs – Part 4: The New Partnership Playbook
July 10, 2026
Experts discuss how biopharma partnerships are evolving, as companies look beyond transactional supplier relationships toward more integrated, strategic, and collaborative models
14 min read
Biopharma Vital Signs – Part 3: Pressure Points
July 3, 2026
From clinical translation and regulatory expectations to manufacturing readiness, capital constraints, and commercial viability, experts identify the pressure points shaping the path from discovery to market
13 min read
Biopharma Vital Signs – Part 2: Emerging Trends
June 26, 2026
Industry experts discuss the trends reshaping biotech and biopharma development – from complex modalities and manufacturing pressures to AI, funding constraints, and the growing need to plan for commercialization earlier
9 min read
Cell & Gene
Development & Clinical
Outsourcing
Regulation & Standards
Business & Trends
Technology & Manufacturing
Roving Reporter Asks: What Are Recent Breakthroughs Telling Us About the CGT Field’s Maturity?
June 25, 2026
IBTV speaks with industry leaders at ARM’s Meeting on the Med 2026 to explore what recent clinical, regulatory, and commercial milestones reveal about the next phase of cell and gene therapy
Earendil: A Blueprint for a Multipolar Life Sciences Era
By Joe Renny
June 5, 2026
The $787M financing points to a new global architecture in biotech
5 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
